Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Andraos, R., Qian, Z., Bonenfant, D., Rubert, J., Vangrevelinghe, E., Scheufler, C., Marque, F., Regnier, C.H., De Pover, A., Ryckelynck, H., Bhagwat, N., Koppikar, P., Goel, A., Wyder, L., Tavares, G., Baffert, F., Pissot-Soldermann, C., Manley, P.W., Gaul, C., Voshol, H., Levine, R.L., Sellers, W.R., Hofmann, F., Radimerski, T.(2012) Cancer Discov 2: 512-523
- PubMed: 22684457 
- DOI: 10.1158/2159-8290.CD-11-0324
- Primary Citation of Related Structures:  
3UGC - PubMed Abstract: 
Janus kinase (JAK) inhibitors are being developed for the treatment of rheumatoid arthritis, psoriasis, myeloproliferative neoplasms, and leukemias. Most of these drugs target the ATP-binding pocket and stabilize the active conformation of the JAK kinases ...